newsfilter
← Latest News
Business Wire·

AlloVir Announces $126.6 Million Registered Direct Offering

Proceeds Support the Completion of Three Global Phase 3 Registrational Trials for Posoleucel and Global Regulatory Filings AlloVir, Inc. (NASDAQ:ALVR), a late clinical-stage allogeneic T-cell immunotherapy company, today announced that it has entered